ArticleFrontiers in immunology2025

Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial.

Yueyun Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.